ba0005oc1.4 | Clinical trials and osteoporosis treatment | ECTS2016
Ferrari S
, Adami S
, Brown J P
, Cosman F
, Czerwiński E
, de Gregorio L H
, Malouf J
, Reginster J-Y
, Daizadeh N S
, Wang A
, Wagman R B
, Lewiecki E M
The relationship between BMD T-score and FX risk has not been established in patients receiving osteoporosis therapy. In the FREEDOM Extension study, continuous DMAb therapy for up to 10 years increased BMD levels with no therapeutic plateau at lumbar spine or TH [Bone et al, ASBMR 2015]. Such improvements would only be meaningful if associated with FX reductions. We investigated the relationship between TH BMD T-score and NVFX in women who received DMAb during FREEDOM and tho...